Trial reportEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology2023
A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): one-year results of the BIOMAG-I first-in-human study.
Trial report in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
BIOTRONIK - Safety and Clinical Performance of the - Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries
3rd Generation Resorbable Magnesium Scaffolds vs Biodegradable Polymer Drug Eluting Stents in Patients With Non ST-segment Elevation Acute Coronary Syndromes: the RESORB-ACS Randomized Clinical Trial
Who cites it
28 citing papers in PubMed, 49 citations in OpenAlex.
- Outcomes of Patients With High-Risk Plaques Treated With a Bioresorbable Magnesium Scaffold: Insights From the BIOMAG-I Study.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Trial
- Trial
- Advances in Functional Vascular Stents for Cardiovascular Therapy with Drug Delivery and Computational Design.Pharmaceutics · 2026Review
- A Comparison of Performance of the Different Generations of Magnesium-Based Bioresorbable Coronary Stents.Journal of clinical medicine · 2026Review
- Iron-Based Bioresorbable Scaffold in Contemporary: A Viewpoint on Design Rationale, Early Evidence, and Unresolved Questions.JACC. Asia · 2026Article
- Bioresorbable Scaffolds: Ready for a Rematch?Current cardiology reports · 2026Review
- One-year outcomes of bioresorbable magnesium scaffold implantation in complex coronary lesions.Frontiers in cardiovascular medicine · 2026Article
- Development and translation of biodegradable metal stents: from heart to brain.Regenerative biomaterials · 2026Review
- Magnesium-based bioresorbable flow diverter for intracranial aneurysms: a pilot study of biocompatibility and bioresorption in a rabbit vascular model.Journal of neurointerventional surgery · 2025Article
- Revisiting Bioresorbable Scaffolds in Light of the SCAAR Study.Journal of the Society for Cardiovascular Angiography & Interventions · 2025Article
- Coronary Stents: All Those Trials.The International journal of angiology : official publication of the International College of Angiology, Inc · 2025Review
- Late Thrombosis of First-Generation Bioresorbable Scaffold Site Treated With Novel Resorbable Magnesium Scaffold.JACC. Case reports · 2025Article
- Long-Term Outcome of Percutaneous Coronary Intervention Using Absorb Bioresorbable Scaffold: A SCAAR Study.Journal of the Society for Cardiovascular Angiography & Interventions · 2025Article
- Clinical outcomes of the third-generation resorbable magnesium scaffold for coronary artery lesions: three-year results of the BIOMAG-I study.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025Article
- Absorb® bioresorbable scaffold in "established" versus "off-label" coronary lesions: 5-year data from the GABI-R® registry.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Observational
- The Impact of Underlying Plaque Characteristics Following the Third-Generation Resorbable Magnesium Scaffold Implantation: An Intravascular OCT Assessment up to 12-Months.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025Article
- A real-world experience with a thin-strut bioresorbable vascular scaffold system: a single-centre study.AsiaIntervention · 2025Article
- The Safety and Efficacy Profile of Magnesium-Based Bioresorbable Coronary Stents as Compared to Poly-L-Lactic Acid-Based Bioresorbable and Contemporary Drug-Eluting Coronary Stents-A Systematic Review.Cardiology research and practice · 2025Review
- Peripheral artery disease and local drug delivery: a review of disease pathology and drug delivery systems for therapy below the knee.Experimental biology and medicine (Maywood, N.J.) · 2025Review
- Progress in research and development of biodegradable metallic vascular stents.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 11 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe third-generation coronary sirolimus-eluting magnesium scaffold, DREAMS 3G, is a further development of the DREAMS 2G (commercial name Magmaris), aiming to provide performance outcomes similar to drug-eluting stents (DES).
aimsThe BIOMAG-I study aims to assess the safety and performance of this new-generation scaffold.
methodsThis is a prospective, multicentre, first-in-human study with clinical and imaging follow-up scheduled at 6 and 12 months. The clinical follow-up will continue for 5 years.
resultsA total of 116 patients with 117 lesions were enrolled. At 12 months, after completion of resorption, in-scaffold late lumen loss was 0.24±0.36 mm (median 0.19, interquartile range 0.06-0.36). The minimum lumen area was 4.95±2.24 mm² by intravascular ultrasound and 4.68±2.32 mm² by optical coherence tomography. Three target lesion failures were reported (2.6%, 95% confidence interval: 0.9-7.9), all clinically driven target lesion revascularisations. Cardiac death, target vessel myocardial infarction and definite or probable scaffold thrombosis were absent.
conclusionsData at the end of the resorption period of DREAMS 3G showed that the third-generation bioresorbable magnesium scaffold is clinically safe and effective, making it a possible alternative to DES. CLINICALTRIALS: gov: NCT04157153.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.